TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This trial will enroll patients that have been diagnosed with a transient ischemic attack
(TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a
minor stroke faces the possibility of long-term disability and even death, regardless of
treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or
worsen over the hours or days immediately following a stroke. The purpose of this research
trial is to study the effects of a clot-dissolving drug, tenecteplase (TNK-tPA), as a
treatment for patients who arrive within twelve hours from stroke onset. This study is
attempting to see if TNK-tPA given through a vein in the arm (intravenous) to patients is a
safe treatment for stroke patients. Neither the safety nor the effectiveness of this
treatment has been proven yet.
This trial will be conducted at several site in Canada.
Dr Michael Hill and Dr. Shelagh Coutts are the Principal Investigators of this trial,
coordinated at the University of Calgary, Foothills Medical Centre.
Phase:
Phase 2
Details
Lead Sponsor:
University of Calgary
Collaborators:
Centre Hospitalier Universitaire de Québec, CHU de Québec CHU de Quebec-Universite Laval Hopital Charles Lemoyne Ottawa Hospital Research Institute Université de Sherbrooke Vancouver General Hospital Vancouver Island Health Authority